The discovery of 3, 3-dimethyl-1, 2, 3, 4-tetrahydroquinoxaline-1-carboxamides as AMPD2 inhibitors with a novel mechanism of action. (15th January 2023)

• Record Type: Journal Article
• Authors: Kitao, Yuki; Saito, Tadataka; Watanabe, Satoshi; Ohe, Yasuhiro; Takahashi, Koichi; Akaki, Tatsuo; Adachi, Tsuyoshi; Doi, Satoki; Yamanaka, Kenji; Murai, Yasutaka; Oba, Makoto; Suzuki, Takayoshi
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 80(2023)
• Publication Date: 2023-01-15
• Subjects: AMPD2 inhibitor -- Allosteric modulation -- Conformational change; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2022.129110
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: AMP deaminase 2 (AMPD2) has been thought to play an important role in energy homeostasis and immuno-oncology, while selective AMPD2 inhibitors are highly demanded to clarify the physiological function of AMPD2. In this report, we describe selective AMPD2 inhibitors inducing allosteric modulation. Based on hypothesis that compounds that exhibit increased inhibition by preincubation would cause conformational change of the enzyme, starting from HTS hit compound 4, we discovered compound 8 through the SAR study. From X-ray structural information of 8, this chemical series has a novel mechanism of action that changes the substrate pocket to prevent AMP from binding. Further elaboration of compound 8 led to the tool compound 21 which exhibited potent inhibitory activity of AMPD2 in ex vivo evaluation of mouse liver.